Verve Therapeutics, Inc. (VERV)
NASDAQ: VERV · Real-Time Price · USD
4.610
+0.240 (5.49%)
At close: May 20, 2025, 4:00 PM
4.580
-0.030 (-0.65%)
After-hours: May 20, 2025, 7:03 PM EDT
Verve Therapeutics Stock Forecast
Stock Price Forecast
According to 4 professional analysts, the 12-month price target for Verve Therapeutics stock ranges from a low of $15 to a high of $39. The average analyst price target of $25.75 forecasts a 458.57% increase in the stock price over the next year.
Price Target: $25.75 (+458.57%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Apr 15, 2025.
Analyst Ratings
The average analyst rating for Verve Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 5 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Hold → Buy Upgrades n/a | Hold → Buy | Upgrades | n/a | n/a | Apr 15, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $18 → $24 | Strong Buy | Maintains | $18 → $24 | +420.61% | Apr 15, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $32 → $39 | Strong Buy | Maintains | $32 → $39 | +745.99% | Apr 15, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $15 → $25 | Strong Buy | Maintains | $15 → $25 | +442.30% | Apr 14, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Mar 25, 2025 |
Financial Forecast
Revenue This Year
24.64M
from 32.33M
Decreased by -23.81%
Revenue Next Year
13.17M
from 24.64M
Decreased by -46.54%
EPS This Year
-2.78
from -2.35
EPS Next Year
-2.72
from -2.78
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 54.9M | 33.6M | 47.3M | ||
| Avg | 24.6M | 13.2M | 13.9M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 69.9% | 36.4% | 258.7% | ||
| Avg | -23.8% | -46.5% | 5.7% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.43 | -2.28 | -2.02 | ||
| Avg | -2.78 | -2.72 | -2.53 | ||
| Low | -3.10 | -3.03 | -3.33 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.